The few treatment options available for XDR TB are less effective and associated with worse outcomes than traditional antibiotic therapies for TB. Inappropriate management can have life-threatening results.
This includes strengthening political will throughout affected countries to reduce the burden of TB, rapid accurate bacteriological diagnosis, a secure supply of high quality drugs, supervised and standardised treatment, and recording of the outcome of every single patient at the end of treatment. XDR-TB involves resistance to the two most powerful anti-TB drugs, isoniazid and rifampicin, also known as multidrug-resistance (MDR-TB), in addition to resistance to any of the fluoroquinolones (such as levofloxacin or moxifloxacin) and to at least one of the three injectable second-line drugs (amikacin, capreomycin or kanamycin). XDR TB is of special concern for persons with HIV infection or other conditions that can weaken the immune system. XDR TB is a rare form of the disease that is resistant to the drugs routinely used to treat tuberculosis infections and is extremely difficult to treat. In this regard, if a patient wilfully refuses treatment and, as a result, is a danger to the public, the serious threat posed by XDR-TB means that limiting that individual's human rights may be necessary to protect the wider public. TB patients whose symptoms do not improve after a few weeks of treatment for TB and a
24 January 2007. WHO places prevention and care of XDR-TB as a priority through the strengthening of basic TB control and the necessary interventions to cure existing cases. Globally, 8,703 patients with XDR-TB were enrolled in treatment in 70 countries and territories in 2017. The Siracusa principles are: Responsibilities of TB treatment-providers to their patients are detailed in The International Standards for Tuberculosis Care (7). Sister died from XDR-TB Before Nix-TB, 1 year of treatment Young male Contracted XDR-TB at 17 Before Nix-TB, 6-7 years of treatment Both patients cured of TB within 6 months, WHO strongly recommends that governments must ensure, as their top priority, that every patient has access to high quality TB diagnosis and treatment for TB and drug-resistant forms of TB. Because XDR TB is resistant to the most potent TB drugs, the remaining treatment options are less effective, have more side effects, and are more expensive. A person with these symptoms does not necessarily have XDR-TB, but they should see a physician for diagnosis and a treatment plan. The restriction is provided for and carried out in accordance with the law; The restriction is in the interest of a legitimate objective of general interest; The restriction is strictly necessary in a democratic society to achieve the objective; There are no less intrusive and restrictive means available to reach the same objective; The restriction is based on scientific evidence and not drafted or imposed arbitrarily i.e. The publication of a PLoS Medicine journal report (4) has highlighted again the issues around compulsory treatment, particularly in relation to drug-resistant TB. Treating and curing drug-resistant TB is complicated.
It also includes ensuring that the capacity to identify and treat drug-resistant TB is in place, with a secure supply of second-line anti-TB drugs required for treating multidrug-resistant TB obtained through the Green Light Committee (in resource-limited settings) (1), as well as implementing good infection control procedures. Extensively drug-resistant TB (XDR TB) is a rare type of MDR TB that is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin). These measures are currently the best approach to the prevention and care of XDR-TB and were listed among the recommendations supported by international health experts at the first meeting of the WHO Global Task Force on XDR-TB in October 2006 (2). Coronavirus disease outbreak (COVID-2019), Coronavirus disease outbreak (COVID-19) », Supranational Reference Laboratory Network, Addressing needs of vulnerable populations, Global Task Force on TB impact measurement, Global Task Force on Digital Health for TB, TPPs and priority digital health products for TB, (1) Green Light Committee application instructions, 2010 [pdf 163kb], (2) Report of the meeting of the WHO Global Task Force on XDR-TB, 2006, (3) Good practice in legislation and regulations for TB control: an indicator of political will, 2001 [pdf 163kb], (4) XDR-TB in South Africa: No Time for Denial or Complacency, PLoS Med 4(1), 2007, (5) The patients' charter for tuberculosis care, 2006, (6) Siracusa principles on the limitation and derogation provisions in the International Covenant on Civil and Political Rights, 1985, (7) International standards for tuberculosis care, 2006. WHO's position with respect to the legal and ethical issues surrounding compulsory TB treatment was published in 2001 (3) with the specific purpose of ensuring prevention and control is strengthened within a legal and human rights' framework. It also fully supports the rights and responsibilities of TB patients as recommended in the Patients' Charter for TB Care (5). In this regard, if a patient wilfully refuses treatment and, as a result, is a danger to the public, the serious threat posed by XDR-TB means that limiting that individual's human rights may …
Tuberculosis management refers to the medical treatment of the infectious disease tuberculosis (TB).. in an unreasonable or otherwise discriminatory manner. This was a small (2%) increase compared with 2016. However in 20 of these countries the number enrolled on treatment was less than the number of cases notified to WHO. Therefore, interference with freedom of movement when instituting quarantine or isolation for a communicable disease such as MDR-TB and XDR-TB may be necessary for the public good, and could be considered legitimate under international human rights law. This must be viewed as a last resort, and justified only after all voluntary measures to isolate such a patient have failed. XDR-TB, an abbreviation for extensively drug-resistant tuberculosis (TB), is a form of TB which is resistant to at least four of the core anti-TB drugs.
This includes strengthening political will throughout affected countries to reduce the burden of TB, rapid accurate bacteriological diagnosis, a secure supply of high quality drugs, supervised and standardised treatment, and recording of the outcome of every single patient at the end of treatment. XDR-TB involves resistance to the two most powerful anti-TB drugs, isoniazid and rifampicin, also known as multidrug-resistance (MDR-TB), in addition to resistance to any of the fluoroquinolones (such as levofloxacin or moxifloxacin) and to at least one of the three injectable second-line drugs (amikacin, capreomycin or kanamycin). XDR TB is of special concern for persons with HIV infection or other conditions that can weaken the immune system. XDR TB is a rare form of the disease that is resistant to the drugs routinely used to treat tuberculosis infections and is extremely difficult to treat. In this regard, if a patient wilfully refuses treatment and, as a result, is a danger to the public, the serious threat posed by XDR-TB means that limiting that individual's human rights may be necessary to protect the wider public. TB patients whose symptoms do not improve after a few weeks of treatment for TB and a
24 January 2007. WHO places prevention and care of XDR-TB as a priority through the strengthening of basic TB control and the necessary interventions to cure existing cases. Globally, 8,703 patients with XDR-TB were enrolled in treatment in 70 countries and territories in 2017. The Siracusa principles are: Responsibilities of TB treatment-providers to their patients are detailed in The International Standards for Tuberculosis Care (7). Sister died from XDR-TB Before Nix-TB, 1 year of treatment Young male Contracted XDR-TB at 17 Before Nix-TB, 6-7 years of treatment Both patients cured of TB within 6 months, WHO strongly recommends that governments must ensure, as their top priority, that every patient has access to high quality TB diagnosis and treatment for TB and drug-resistant forms of TB. Because XDR TB is resistant to the most potent TB drugs, the remaining treatment options are less effective, have more side effects, and are more expensive. A person with these symptoms does not necessarily have XDR-TB, but they should see a physician for diagnosis and a treatment plan. The restriction is provided for and carried out in accordance with the law; The restriction is in the interest of a legitimate objective of general interest; The restriction is strictly necessary in a democratic society to achieve the objective; There are no less intrusive and restrictive means available to reach the same objective; The restriction is based on scientific evidence and not drafted or imposed arbitrarily i.e. The publication of a PLoS Medicine journal report (4) has highlighted again the issues around compulsory treatment, particularly in relation to drug-resistant TB. Treating and curing drug-resistant TB is complicated.
It also includes ensuring that the capacity to identify and treat drug-resistant TB is in place, with a secure supply of second-line anti-TB drugs required for treating multidrug-resistant TB obtained through the Green Light Committee (in resource-limited settings) (1), as well as implementing good infection control procedures. Extensively drug-resistant TB (XDR TB) is a rare type of MDR TB that is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin). These measures are currently the best approach to the prevention and care of XDR-TB and were listed among the recommendations supported by international health experts at the first meeting of the WHO Global Task Force on XDR-TB in October 2006 (2). Coronavirus disease outbreak (COVID-2019), Coronavirus disease outbreak (COVID-19) », Supranational Reference Laboratory Network, Addressing needs of vulnerable populations, Global Task Force on TB impact measurement, Global Task Force on Digital Health for TB, TPPs and priority digital health products for TB, (1) Green Light Committee application instructions, 2010 [pdf 163kb], (2) Report of the meeting of the WHO Global Task Force on XDR-TB, 2006, (3) Good practice in legislation and regulations for TB control: an indicator of political will, 2001 [pdf 163kb], (4) XDR-TB in South Africa: No Time for Denial or Complacency, PLoS Med 4(1), 2007, (5) The patients' charter for tuberculosis care, 2006, (6) Siracusa principles on the limitation and derogation provisions in the International Covenant on Civil and Political Rights, 1985, (7) International standards for tuberculosis care, 2006. WHO's position with respect to the legal and ethical issues surrounding compulsory TB treatment was published in 2001 (3) with the specific purpose of ensuring prevention and control is strengthened within a legal and human rights' framework. It also fully supports the rights and responsibilities of TB patients as recommended in the Patients' Charter for TB Care (5). In this regard, if a patient wilfully refuses treatment and, as a result, is a danger to the public, the serious threat posed by XDR-TB means that limiting that individual's human rights may …
Tuberculosis management refers to the medical treatment of the infectious disease tuberculosis (TB).. in an unreasonable or otherwise discriminatory manner. This was a small (2%) increase compared with 2016. However in 20 of these countries the number enrolled on treatment was less than the number of cases notified to WHO. Therefore, interference with freedom of movement when instituting quarantine or isolation for a communicable disease such as MDR-TB and XDR-TB may be necessary for the public good, and could be considered legitimate under international human rights law. This must be viewed as a last resort, and justified only after all voluntary measures to isolate such a patient have failed. XDR-TB, an abbreviation for extensively drug-resistant tuberculosis (TB), is a form of TB which is resistant to at least four of the core anti-TB drugs.